Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Rybak

Showing results (31-40 of 137) with videos related to

Pageof 14
Sort By:
Pharmacotherapy|September 1, 1995
Vancomycin-resistant enterococciM J Rybak, S M Palmer
Pharmacotherapy|September 1, 1996
Vancomycin-resistant enterococciS M Palmer, M J Rybak
Drug Intelligence & Clinical Pharmacy|November 1, 1986
Hematological effects associated with beta-lactam useL M Babiak, M J Rybak
Antimicrobial Agents and Chemotherapy|September 16, 1998
Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methodsJ R Aeschlimann, M J Rybak
Clinical Pharmacy|February 1, 1986
Aminoglycoside pharmacokinetics in patients with spinal cord injuryV Tutag-Lehr, M J Rybak
DICP : the Annals of Pharmacotherapy|November 1, 1989
Ofloxacin: a reviewM A Smythe, M J Rybak
Antimicrobial Agents and Chemotherapy|February 22, 2001
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic modelE A Coyle, M J Rybak
Antimicrobial Agents and Chemotherapy|February 13, 2001
Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetationsR L Akins, M J Rybak
Drugs|February 24, 2001
Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment optionsM J Rybak, R L Akins
Antimicrobial Agents and Chemotherapy|March 1, 1996
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clotsS M Palmer, M J Rybak
Pageof 14

Showing results (31-40 of 137) with videos related to

Sort By:
Pageof 14
Pharmacotherapy|September 1, 1995
Vancomycin-resistant enterococciM J Rybak, S M Palmer
Pharmacotherapy|September 1, 1996
Vancomycin-resistant enterococciS M Palmer, M J Rybak
Drug Intelligence & Clinical Pharmacy|November 1, 1986
Hematological effects associated with beta-lactam useL M Babiak, M J Rybak
Antimicrobial Agents and Chemotherapy|September 16, 1998
Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methodsJ R Aeschlimann, M J Rybak
Clinical Pharmacy|February 1, 1986
Aminoglycoside pharmacokinetics in patients with spinal cord injuryV Tutag-Lehr, M J Rybak
DICP : the Annals of Pharmacotherapy|November 1, 1989
Ofloxacin: a reviewM A Smythe, M J Rybak
Antimicrobial Agents and Chemotherapy|February 22, 2001
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic modelE A Coyle, M J Rybak
Antimicrobial Agents and Chemotherapy|February 13, 2001
Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetationsR L Akins, M J Rybak
Drugs|February 24, 2001
Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment optionsM J Rybak, R L Akins
Antimicrobial Agents and Chemotherapy|March 1, 1996
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clotsS M Palmer, M J Rybak
Pageof 14